no title
Copyright © 2019 Elsevier Masson SAS. Tous droits réservés..
The treatment of atopic dermatitis is based on the use of topical steroids and emollients. When AD is resistant to a well-conducted topical treatment, phototherapy or systemic therapeutics can be used: ciclosporin, methotrexate, azathioprine or mycophenolate mofetil. However, the therapeutic landscape of AD is changing dramatically because of the approval of dupilumab (an anti-IL4/IL13 biologic therapy) and the possible future arrival of other biologicals (anti-IL13, anti-IL31…), and JAK inhibitors. © 2019 Elsevier Masson SAS. All rights reserved.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Annales de dermatologie et de venereologie - 146(2019), 12S3 vom: 30. Dez., Seite 12S76-12S84 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Les traitements systémiques de la dermatite atopique: Systemic treatments of atopic dermatitis |
|---|
| Beteiligte Personen: |
Lacour, J-P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.07.2020 Date Revised 06.07.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0151-9638(20)30017-X |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305935666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305935666 | ||
| 003 | DE-627 | ||
| 005 | 20231225122242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/S0151-9638(20)30017-X |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1019.xml |
| 035 | |a (DE-627)NLM305935666 | ||
| 035 | |a (NLM)31997736 | ||
| 035 | |a (PII)S0151-9638(20)30017-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lacour, J-P |e verfasserin |4 aut | |
| 246 | 3 | 3 | |a Les traitements systémiques de la dermatite atopique: Systemic treatments of atopic dermatitis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2020 | ||
| 500 | |a Date Revised 06.07.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Masson SAS. Tous droits réservés. | ||
| 520 | |a The treatment of atopic dermatitis is based on the use of topical steroids and emollients. When AD is resistant to a well-conducted topical treatment, phototherapy or systemic therapeutics can be used: ciclosporin, methotrexate, azathioprine or mycophenolate mofetil. However, the therapeutic landscape of AD is changing dramatically because of the approval of dupilumab (an anti-IL4/IL13 biologic therapy) and the possible future arrival of other biologicals (anti-IL13, anti-IL31…), and JAK inhibitors. © 2019 Elsevier Masson SAS. All rights reserved | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atopic dermatitis | |
| 650 | 4 | |a Atopic eczema | |
| 650 | 4 | |a Dermatite atopique | |
| 650 | 4 | |a Eczéma atopique | |
| 650 | 4 | |a Systemic treatment | |
| 650 | 4 | |a Traitement systémique | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 650 | 7 | |a Histamine H1 Antagonists |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Phosphodiesterase 4 Inhibitors |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 650 | 7 | |a Janus Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Annales de dermatologie et de venereologie |d 1986 |g 146(2019), 12S3 vom: 30. Dez., Seite 12S76-12S84 |w (DE-627)NLM000154113 |x 0151-9638 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2019 |g number:12S3 |g day:30 |g month:12 |g pages:12S76-12S84 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0151-9638(20)30017-X |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2019 |e 12S3 |b 30 |c 12 |h 12S76-12S84 | ||